Laparoscopic Sleeve Gastrectomy Versus Roux-en-Y Gastric Bypass
Primary Purpose
Morbid Obesity
Status
Unknown status
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Laparoscopic sleeve gastrectomy
Laparoscopic Roux-en-Y gastric bypass
Sponsored by
About this trial
This is an interventional treatment trial for Morbid Obesity focused on measuring Sleeve gastrectomy, Roux-en-Y gastric bypass, Excess weight loss, Quality of life
Eligibility Criteria
Inclusion Criteria:
- BMI >40 and < 60 kg/m2
- No contraindication to any of the procedures
- No contraindication to general anesthesia
- No known addiction
- Patient able to provide informed consent
Exclusion Criteria:
- Contraindication to general anesthesia
- Known psychiatric pathology
- Pregnancy
- Previous major digestive surgery
- Immunosuppressive treatment including corticoids
- Coagulopathy (INR>1.5) or platelets < 50 000/µl
- Anemia (Hb<10g/dl)
- Severe comorbidity
- Malabsorptive disease or gastro-intestinal disease
- Myocardial infarction in previous year, angina, cardiac failure
Sites / Locations
- Service de Chirurgie Digestive et Endocrinienne
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Sleeve gastrectomy
Roux-en-Y gastric bypass
Arm Description
Laparoscopic sleeve gastrectomy
Laparoscopic Roux-en-Y gastric bypass
Outcomes
Primary Outcome Measures
Excess weight loss at 3 years
% of excess weight loss
Change in excess weight loss
% of excess weight loss
Secondary Outcome Measures
Nutritional status and vitamin deficiency
Albumin
Nutritional status and vitamin deficiency
Pre-albumin
Nutritional status and vitamin deficiency
Vitamin A
Nutritional status and vitamin deficiency
Vitamin D
Nutritional status and vitamin deficiency
Vitamin B9
Nutritional status and vitamin deficiency
Vitamin B12
Glycolipid profile
Fasting plasma glucose
Glycolipid profile
Serum insulin
Glycolipid profile
HbA1c
Glycolipid profile
Triglycerides
Glycolipid profile
Cholesterol (total, HDL, LDL)
Quality of life (Moorehead-Ardelt II, Gastro-intestinal Quality of Life Index (GIQLI))
Moorehead-Ardelt II, Gastro-intestinal Quality of Life Index (GIQLI)
Pain (visual analog scale)
Pain assessment (visual analog scale)
Full Information
NCT ID
NCT02475590
First Posted
May 26, 2015
Last Updated
February 27, 2018
Sponsor
IHU Strasbourg
Collaborators
IRCAD
1. Study Identification
Unique Protocol Identification Number
NCT02475590
Brief Title
Laparoscopic Sleeve Gastrectomy Versus Roux-en-Y Gastric Bypass
Official Title
Laparoscopic Sleeve Gastrectomy Versus Roux-en-Y Gastric Bypass for Morbidly Obese Patients: a Prospective Randomized Clinical Trial
Study Type
Interventional
2. Study Status
Record Verification Date
February 2018
Overall Recruitment Status
Unknown status
Study Start Date
March 2009 (Actual)
Primary Completion Date
July 2015 (Actual)
Study Completion Date
July 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
IHU Strasbourg
Collaborators
IRCAD
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Prospective randomized clinical trial aiming to compare laparoscopic Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) with primary outcome on excess weight loss, and secondary outcomes on nutritional status, glycolipid profile, quality of life and pain assessments.
Detailed Description
No consensus is proposed by the Medical and Surgical societies to define and / or prioritize surgical procedures in obesity surgery. Indications are based on patient's age, sex, dietary habits, the importance of overweight and associated comorbidities and even if rarely admitted, based on knowledge of surgical teams and the cost of interventions. Given the decrease of gastric banding procedures, Roux-en-Y gastro-jejunal bypass is often considered the reference procedure.
The gastric bypass, developed in the 60s, is performed laparoscopically since the early 90s. It allows for a 60% to 70% excess weight loss with control over 75% of comorbidities. It is recommended to follow these patients long-term because late complications can occur. These patients require ongoing information and regular monitoring. They must also have a hyper-protein diet and a vitamin substitute long-term (multivitamins, vitamin B12, calcium ...).
The Sleeve gastrectomy (SG) arises as an alternative to RYGB. It was classically proposed to patients with a BMI greater than 60 and significant comorbidities since the procedure let to a significant weight reduction in patients for whom any other procedure was too difficult to perform. The quality of the weight loss achieved in these patients has led many teams to analyze the results of this intervention without conducting an additional procedure. It appears from the literature that even performed alone, SG presents many benefits.
To clarify the role of sleeve gastrectomy in the bariatric procedures range, the investigators propose to conduct a prospective randomized study to compare laparoscopic sleeve gastrectomy to Roux-en-Y gastric bypass.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Morbid Obesity
Keywords
Sleeve gastrectomy, Roux-en-Y gastric bypass, Excess weight loss, Quality of life
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
100 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Sleeve gastrectomy
Arm Type
Experimental
Arm Description
Laparoscopic sleeve gastrectomy
Arm Title
Roux-en-Y gastric bypass
Arm Type
Experimental
Arm Description
Laparoscopic Roux-en-Y gastric bypass
Intervention Type
Procedure
Intervention Name(s)
Laparoscopic sleeve gastrectomy
Intervention Description
Laparoscopic sleeve gastrectomy
Intervention Type
Procedure
Intervention Name(s)
Laparoscopic Roux-en-Y gastric bypass
Intervention Description
Laparoscopic Roux-en-Y gastric bypass
Primary Outcome Measure Information:
Title
Excess weight loss at 3 years
Description
% of excess weight loss
Time Frame
At 36 months
Title
Change in excess weight loss
Description
% of excess weight loss
Time Frame
At 1, 3, 6, 12, months and every year for 10 years
Secondary Outcome Measure Information:
Title
Nutritional status and vitamin deficiency
Description
Albumin
Time Frame
At 1, 3, 6, 12, 18, 24, 30 and 36 months
Title
Nutritional status and vitamin deficiency
Description
Pre-albumin
Time Frame
At 1, 3, 6, 12, 18, 24, 30 and 36 months
Title
Nutritional status and vitamin deficiency
Description
Vitamin A
Time Frame
At 1, 3, 6, 12, 18, 24, 30 and 36 months
Title
Nutritional status and vitamin deficiency
Description
Vitamin D
Time Frame
At 1, 3, 6, 12, 18, 24, 30 and 36 months
Title
Nutritional status and vitamin deficiency
Description
Vitamin B9
Time Frame
At 1, 3, 6, 12, 18, 24, 30 and 36 months
Title
Nutritional status and vitamin deficiency
Description
Vitamin B12
Time Frame
At 1, 3, 6, 12, 18, 24, 30 and 36 months
Title
Glycolipid profile
Description
Fasting plasma glucose
Time Frame
At 1, 3, 6, 12, 18, 24, 30 and 36 months
Title
Glycolipid profile
Description
Serum insulin
Time Frame
At 1, 3, 6, 12, 18, 24, 30 and 36 months
Title
Glycolipid profile
Description
HbA1c
Time Frame
At 1, 3, 6, 12, 18, 24, 30 and 36 months
Title
Glycolipid profile
Description
Triglycerides
Time Frame
At 1, 3, 6, 12, 18, 24, 30 and 36 months
Title
Glycolipid profile
Description
Cholesterol (total, HDL, LDL)
Time Frame
At 1, 3, 6, 12, 18, 24, 30 and 36 months
Title
Quality of life (Moorehead-Ardelt II, Gastro-intestinal Quality of Life Index (GIQLI))
Description
Moorehead-Ardelt II, Gastro-intestinal Quality of Life Index (GIQLI)
Time Frame
At 1, 3, 6, 12, 18, 24, 30 and 36 months
Title
Pain (visual analog scale)
Description
Pain assessment (visual analog scale)
Time Frame
At 1, 3, 6, 12, 18, 24, 30 and 36 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
BMI >40 and < 60 kg/m2
No contraindication to any of the procedures
No contraindication to general anesthesia
No known addiction
Patient able to provide informed consent
Exclusion Criteria:
Contraindication to general anesthesia
Known psychiatric pathology
Pregnancy
Previous major digestive surgery
Immunosuppressive treatment including corticoids
Coagulopathy (INR>1.5) or platelets < 50 000/µl
Anemia (Hb<10g/dl)
Severe comorbidity
Malabsorptive disease or gastro-intestinal disease
Myocardial infarction in previous year, angina, cardiac failure
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jacques Marescaux, MD
Organizational Affiliation
Strasbourg university hospital, IRCAD, IHU Strasbourg
Official's Role
Principal Investigator
Facility Information:
Facility Name
Service de Chirurgie Digestive et Endocrinienne
City
Strasbourg
ZIP/Postal Code
67 000
Country
France
12. IPD Sharing Statement
Citations:
PubMed Identifier
24196556
Citation
Vix M, Liu KH, Diana M, D'Urso A, Mutter D, Marescaux J. Impact of Roux-en-Y gastric bypass versus sleeve gastrectomy on vitamin D metabolism: short-term results from a prospective randomized clinical trial. Surg Endosc. 2014 Mar;28(3):821-6. doi: 10.1007/s00464-013-3276-x. Epub 2013 Nov 7.
Results Reference
background
PubMed Identifier
23207829
Citation
Vix M, Diana M, Liu KH, D'Urso A, Mutter D, Wu HS, Marescaux J. Evolution of glycolipid profile after sleeve gastrectomy vs. Roux-en-Y gastric bypass: results of a prospective randomized clinical trial. Obes Surg. 2013 May;23(5):613-21. doi: 10.1007/s11695-012-0827-5.
Results Reference
background
PubMed Identifier
27901287
Citation
Ignat M, Vix M, Imad I, D'Urso A, Perretta S, Marescaux J, Mutter D. Randomized trial of Roux-en-Y gastric bypass versus sleeve gastrectomy in achieving excess weight loss. Br J Surg. 2017 Feb;104(3):248-256. doi: 10.1002/bjs.10400. Epub 2016 Nov 30.
Results Reference
derived
Learn more about this trial
Laparoscopic Sleeve Gastrectomy Versus Roux-en-Y Gastric Bypass
We'll reach out to this number within 24 hrs